Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
1. Bristol Myers Squibb and Pfizer launch direct-to-patient Eliquis option. 2. This initiative aims to enhance access for patients requiring apixaban.
FAQ
Why Bullish?
Direct-to-patient options for Eliquis could increase sales significantly, similar to trends seen with other direct-to-consumer medications, potentially enhancing BMY's market position.
How important is it?
The direct-to-patient initiative can lead to revenue growth through increased patient access, which may positively affect overall market sentiment toward BMY.
Why Long Term?
Successfully expanding patient access can lead to sustained revenue growth over the long term, demonstrated by historical cases with other pharmaceuticals seeing increased adherence.